"Cardinal Health ( NYSE: CAH) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, surpassing the $2.38 consensus estimate by 10.5%. Revenue climbed 19% year-over-year to $65.63 billion, topping the $64.79 billion estimate. Shares surged 8% over the past week to $228.25, significantly outpacing the S&P 500's 23% decline over the same period."
"The healthcare distributor achieved double-digit profit growth across all five operating segments. The Pharmaceutical and Specialty Solutions segment, Cardinal's largest, generated $60.7 billion in revenue, up 19% on brand and specialty pharmaceutical demand. Global Medical Products and Distribution revenue rose 3% to $3.26 billion, but segment profit more than doubled to $37 million, up 106% year-over-year."
"Non-GAAP operating earnings jumped 38% to $877 million, while operating cash flow swung to $686 million from a $396 million outflow in the prior-year quarter. CEO Jason Hollar said, "Our strong second-quarter performance reflects at least double-digit segment profit growth across all five of our operating segments. Our ongoing momentum and the team's consistent execution against our strategic priorities gives us confidence to raise our fiscal 2026 outlook.""
Cardinal Health reported non-GAAP EPS of $2.63 for the second quarter, beating estimates by 10.5%, while revenue increased 19% year-over-year to $65.63 billion. All five operating segments posted double-digit profit growth, led by Pharmaceutical and Specialty Solutions with $60.7 billion in revenue. Non-GAAP operating earnings rose 38% to $877 million and operating cash flow improved to $686 million from a prior-year outflow. Management raised full-year fiscal 2026 EPS guidance to $10.15–$10.35 and increased segment profit targets for Pharma and GMPD. The company completed $750 million in share repurchases, paid a $0.52 quarterly dividend, and continued acquisitions.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]